Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.
Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.
Ann Vasc Surg. 2023 Sep;95:162-168. doi: 10.1016/j.avsg.2023.05.002. Epub 2023 May 22.
End-stage kidney disease (ESKD) is a risk factor for peripheral arterial disease and major adverse limb events following infra-inguinal bypass. Despite comprising an important patient population, ESKD patients are rarely analyzed as a subgroup and are underrepresented in vascular surgery guidelines. This study aims to compare the long-term outcomes of patients with and without ESKD undergoing endovascular peripheral vascular intervention (PVI) for chronic limb-threatening ischemia (CLTI).
CLTI patients with and without ESKD from 2007-2020 were identified in the Vascular Quality Initiative PVI dataset. Patients with prior bilateral interventions were excluded. Patients undergoing femoral-popliteal and tibial interventions were included. Mortality, reintervention, amputation, and occlusion rates at 21 months following intervention were examined. Statistical analyses were completed with the t-test, chi-square, and Kaplan-Meier curves.
The ESKD cohort was younger (66.4 ± 11.8 vs. 71.6 ± 12.1 years, P < 0.001) with higher rates of diabetes (82.2 vs. 60.9%, P < 0.001) the non-ESKD cohort. Long-term follow-up was available for 58.4% (N = 2,128 procedures) of ESKD patients and 60.8% (N = 13,075 procedures) of non-ESKD patients. At 21 months, ESKD patients had a higher mortality (41.7 vs. 17.4%, P < 0.001) and a higher amputation rate (22.3 vs. 7.1%, P < 0.001); however, they had a lower reintervention rate (13.2 vs. 24.6%, P < 0.001).
CLTI patients with ESKD have worse long-term outcomes at 2 years following PVI than non-ESKD patients. Mortality and amputation are higher with ESKD, while the reintervention rate is lower. Development of guidelines within the ESKD population has the potential to improve limb salvage.
终末期肾病(ESKD)是下肢动脉疾病和下肢旁路术后主要不良肢体事件的危险因素。尽管 ESKD 患者构成了一个重要的患者群体,但他们很少作为亚组进行分析,并且在血管外科学指南中代表性不足。本研究旨在比较接受血管腔内外周血管介入(PVI)治疗慢性肢体威胁性缺血(CLTI)的合并和不合并 ESKD 的患者的长期结果。
从 2007 年至 2020 年,在血管质量倡议 PVI 数据库中确定了合并和不合并 ESKD 的 CLTI 患者。排除了有双侧介入治疗史的患者。纳入接受股腘和胫腓部介入治疗的患者。在介入治疗后 21 个月时,检查死亡率、再介入、截肢和闭塞率。采用 t 检验、卡方检验和 Kaplan-Meier 曲线进行统计学分析。
ESKD 组年龄较小(66.4 ± 11.8 岁 vs. 71.6 ± 12.1 岁,P < 0.001),糖尿病发生率较高(82.2% vs. 60.9%,P < 0.001)。ESKD 患者的长期随访率为 58.4%(N = 2128 例手术),非 ESKD 患者的长期随访率为 60.8%(N = 13075 例手术)。在 21 个月时,ESKD 患者的死亡率更高(41.7% vs. 17.4%,P < 0.001)和截肢率更高(22.3% vs. 7.1%,P < 0.001);然而,他们的再介入率较低(13.2% vs. 24.6%,P < 0.001)。
接受 PVI 治疗的 CLTI 合并 ESKD 患者在 2 年时的长期结果比非 ESKD 患者差。ESKD 患者的死亡率和截肢率较高,而再介入率较低。在 ESKD 人群中制定指南有可能提高肢体存活率。